Overview Bosentan in the Treatment of Giant Cell Arteritis Status: NOT_YET_RECRUITING Trial end date: 2029-09-01 Target enrollment: Participant gender: Summary The purpose of this study is to determine whether a treatment with 3 months of bosentan associated to standard therapy might be superior to glucocorticoids alone in term of failure free survival at 12 monthsPhase: PHASE2 Details Lead Sponsor: Assistance Publique - Hpitaux de ParisTreatments: BosentanGlucocorticoids